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تقييم مستويات جلوبيولني املناعي A املفرز يف اللعاب لدى مرضى السكري 
وعالقته مع أعراض الفم واألسنان
�سهال كاكوي، بهاره ح�سيني، علي اأكرب حاجدو�ست، مويجن �سنجاري، اأحمد غالم ح�سينيان ، وحيد اف�سار
abstract: Objectives: Oral and dental manifestations in diabetic patients can arise due to numerous factors, 
including elevated salivary secretory immunoglobulin A (s-IgA) levels. This study aimed to evaluate s-IgA 
concentrations in patients with type 2 diabetes mellitus (T2DM) and to investigate the association between s-IgA 
levels and oral and dental manifestations of T2DM. Methods: This cross-sectional descriptive study was carried out 
between October 2011 and September 2012 in Kerman, Iran, and included 260 subjects (128 patients with T2DM 
and 132 healthy controls). Unstimulated salivary samples were collected from all subjects and s-IgA levels were 
determined using the immunoturbidimetric method. The oral cavities and teeth of T2DM patients were evaluated 
for oral and dental manifestations. Results: Both diabetic and control subjects with higher concentrations of s-IgA 
had significantly higher numbers of decayed, missing or filled teeth (DMFT) and periodontal index (PDI) scores 
(P <0.050). s-IgA levels were significantly higher in subjects with oral candidiasis (P <0.050). Among diabetic 
patients, significantly higher s-IgA levels were concomitant with xerostomia and denture stomatitis (P ≤0.050). 
There were no significant differences between s-IgA concentrations and other oral or dental manifestations in 
either group. Conclusion: Individuals with a greater number of DMFT, a higher PDI score and oral candidiasis had 
significantly higher s-IgA levels. s-IgA levels were not significantly higher among diabetic patients in comparison 
to the control group. However, significantly higher s-IgA levels occurred with xerostomia and denture stomatitis 
in diabetic patients. In addition, s-IgA was significantly higher in patients with uncontrolled diabetes compared to 
those with controlled diabetes.
Keywords: Diabetes Mellitus; Saliva; Secretory Immunoglobulin A; Oral Manifestations; Iran.
امللخ�ص: الهدف: اأعرا�ض الفم والأ�سنان يف مر�سى ال�سكري ميكن اأن تن�ساأ نتيجة لعوامل عديدة، مبا يف ذلك ارتفاع م�ستويات جلوبيولني 
املناعي A املفرز يف اللعاب. هدفت هذه الدرا�سة اإىل تقييم تركيز جلوبيولني املناعي A املفرز يف لعاب املر�سى الذين يعانون من النوع 
2 من داء ال�سكري ولتقييم ارتباط م�ستويات جلوبيولني املناعي A املفرز واأعرا�ض الفم والأ�سنان. الطريقة: اأجريت هذه الدرا�سة الو�سفية 
132 من  2 و  260 �سخ�سا )128 من مر�سى ال�سكري من النوع  اإيران، و�سملت  2012 يف كرمان،  2011 و�سبتمرب  اأكتوبر  امل�ستعر�سة بني 
ال�سحاء(. مت جمع عينات اللعاب غرياملحفز من جميع امل�ساركني ومت حتديد م�ستويات جلوبيولني املناعي A با�ستخدام طريقة قيا�ض 
التعكر املناعي. مت تقييم جتاويف الأ�سنان والفم ملر�سى ال�سكري. النتائج: كان ال�سحاء ومر�سى ال�سكري الذين لديهم تركيزات اأعلى من 
م�ستويات جلوبيولني املناعي A لديهم ن�سبة اأعلى اإح�سائيا من الأ�سنان النخرة واملفقودة اأو بها ح�سو اأ�سنان ودرجات موؤ�رس اللثة اأعلى 
)P >0.050(. وكانت م�ستويات جلوبيولني املناعي A اأعلى بكثري يف امل�ساركني الذين لديهم داء املبي�سات الفموي )P >0.050(. ويف مر�سى 
.)P ≤0.050( املرتفعة اإح�سائيا م�ساحبة جلفاف الفم والتهاب الفم امل�ساحب لطقم الأ�سنان A ال�سكري، كانت م�ستويات جلوبيولني املناعي
مل توجد فروق اخرى ذات دللة اإح�سائية بني م�ستويات جلوبيولني املناعي A و اأعرا�ض الفم اأو الأ�سنان يف اأي من املجموعتني )ال�سكري 
والأ�سحاء(. اخلال�صة: ال�سخا�ض الذين لديهم اأ�سنان نخرة اأومفقودة اأو بها ح�سو اأ�سنان ودرجات موؤ�رس اللثة مرتفعة ولديهم داء املبي�سات 
الفموي لديهم ن�سبة اأعلى بكثري يف م�ستويات جلوبيولني املناعي A. ولكن لي�ض هناك فرق اإح�سائي يف م�ستويات جلوبيولني املناعي 
 A اإح�سائية  يف م�ستويات جلوبيولني املناعي  الأ�سحاء. ومع ذلك، فهناك زيادة  التحكم  ال�سكري مقارنة مع جمموعة  A لدى مر�سى 
عند الأ�سخا�ض امل�سابني بجفاف الفم والتهاب الفم امل�ساحب لطقم الأ�سنان يف مر�سى ال�سكري. بالإ�سافة اإىل ذلك، فاإن التهاب الفم 
امل�ساحب لطقم الأ�سنان اأعلى بكثري يف املر�سى الذين يعانون من مر�ض ال�سكري غري املن�سبط مقارنة مع اأولئك امل�سابني بداء ال�سكري 
املن�سبط بالعالج.
مفتاح الكلمات: مر�ض ال�سكري؛ اللعاب؛ جلوبيولني املناعي A؛ اأعرا�ض الفم؛ اإيران.
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Advances in Knowledge
- To the best of the authors’ knowledge, little information exists regarding the probable association between salivary secretory 
immunoglobulin A (s-IgA) levels and oral and dental manifestations in patients with type 2 diabetes (T2DM). 
Advances in Patient Care
- Determination of the salivary components of patients with T2DM could play a fundamental role in predicting, detecting and managing 
oral and dental manifestations of the disease. Based on the results of this study, it is recommended that patients exhibiting a change or 
decrease in their s-IgA levels undergo periodic oral health evaluations.
Type 2 diabetes mellitus (t2dm) is one of the most prevalent metabolic disorders worldwide; by 2025, approximately 320 million 
people will have the disease.1 The disease has a wide 
range of signs and symptoms and manifests differently 
in various organs. In the oral cavity, manifestations 
of diabetes can include a dry or burning mouth, 
periodontal diseases, bone loss, dental abscesses, 
fungal and bacterial infections, oral lichen planus and 
delayed wound healing.1,2 
Immunoglobulin A (IgA) and immunoglobulin G 
affect oral cavity microorganisms in the saliva, gingival 
sulcular fluid and plasma.3 These antibodies prevent 
bacterial metabolism and adhesion of microorganisms 
to the oral tissue.3 Although there are many non-
specific defensive elements in the saliva, such as 
lactoferrin and lysozymes, salivary secretory IgA 
(s-IgA) is the foremost protective mechanism against 
bacterial colonisation of the oral mucous membranes. 
As s-IgA plays an important role in protecting against 
these pathogens, the antibody might also protect 
against periodontal diseases.4 Changes in salivary 
IgA concentrations in diabetic patients could have an 
effect on their oral health. Several studies have sought 
to determine salivary flow rates and components that 
can affect the progression, symptoms and varieties 
of oral changes in diabetic patients.1,2,5 Overall, 
determining the salivary components of diabetic 
patients can be useful in detecting and managing their 
oral manifestations.5
Previous research has assessed s-IgA levels and oral 
conditions among diabetic patients. A Brazilian study 
reported that diabetic patients with lower s-IgA levels 
had more severe and frequent periodontal disease.4 
However, two Iranian studies yielded different results: 
Mohiti-Ardekani et al. recorded significantly higher 
s-IgA levels in diabetic patients while Bakianian Vaziri 
et al. found no significant differences between diabetic 
and non-diabetic groups.1,5 Other studies have also 
reported conflicting results with regards to s-IgA 
levels and their relationship to various diseases.6,7 The 
current study aimed to compare s-IgA levels between 
healthy subjects and T2DM patients and determine 
the association between s-IgA levels and various oral 
and dental manifestations in diabetic patients. This 
relationship could help determine the prognosis of 
oral diseases in diabetic patients and serve as a guide 
for their dental care.
Methods
This cross-sectional descriptive study was carried 
out between October 2011 and September 2012 in 
Kerman, Iran, and included 260 subjects divided 
into two groups. The first group consisted of 128 
patients with T2DM who routinely attended follow-
up appointments at the Diabetes Center of Shahid 
Bahonar Hospital in Kerman. The non-diabetic control 
group was composed of 132 healthy individuals with 
no history of DM who attended annual check-ups 
at either the Razi Laboratory or the Besat Clinical 
Laboratory in Kerman. Information regarding the 
subjects’ gender, age, diabetes type and medical results 
(including assessments of glycated haemoglobin 
[HbA1C] and fasting blood sugar [FBS] levels) was 
compiled by a trained dental student. Smokers and 
subjects <20 years old were excluded from the study. 
Control subjects were included only if they had FBS 
levels of <100 mg/dL, no systemic disorders and did 
not take medications that affected either IgA secretion 
or its levels in the saliva. A diagnosis of T2DM was 
made with a HbA1C level of ≥6.5%, fasting plasma 
glucose (PG) level of ≥126 mg/dL and a two-hour PG 
level of ≥200 mg/dL. For patients exhibiting classic 
symptoms of hyperglycaemic crises, a random PG 
measurement of ≥200 mg/dL met the criteria for a 
diagnosis of T2DM.8 Known diabetic patients who 
were already taking medicine for lowering blood 
glucose and who had a HbA1C level of ≥6.5% were 
determined to have uncontrolled T2DM. 
The oral mucosa of all subjects was checked 
for abnormalities, including manifestations of oral 
candidiasis (erythematous candidiasis, thrush, angu- 
lar cheilitis, median rhomboid glossitis and denture 
stomatitis), lichenoid reactions and frequent abs-
cesses. The characteristics of any noted lesions and 
their locations were recorded. In addition, a tongue 
blade test was performed on all participants to detect 
xerostomia. The guidelines of the World Health 
Organization for assessing dental cavities were used 
to calculate the number of decayed, missing or filled 
teeth (DMFT).9 The periodontal disease index (PDI) 
were used to evaluate the effect of any periodontal 
disease on the supporting tissues of the oral mucosa. 
Xerostomia was assessed using Fox et al.’s standardised 
questionnaire.10 
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Unstimulated salivary samples were collected 
from all subjects in the morning (between 7:30 
and 9:30 a.m.) after fasting for eight hours and 
having cleaned their mouths and teeth 90 minutes 
beforehand.1 Participants were requested to keep their 
mouths closed for a few moments in order for saliva 
to pool and then hold their heads over a container 
and release, resulting in a sample of 1‒2 mL of saliva.3 
Samples were then frozen to -20 °C and sent to a 
laboratory for testing.11 Concentrations of s-IgA were 
determined using the immunoturbidimetric method 
with measurements obtained from a commercial kit 
(Pars Azmoon Co., Tehran, Iran) and an automated 
continuous flow analyser (AutoAnalyzer, TechniCon 
Systems Inc., Oakland, California, USA).12
Data were analysed using the Statistical Package 
for the Social Sciences (SPSS), Version 17 (IBM 
Corp., Chicago, Illinois, USA). Pearson’s correlation 
coefficient test was used to determine the relationship 
between s-IgA levels and age, HbA1C and FBS. The 
independent t-test was used to compare DMFT and 
PDI indices between the groups.
This study was approved by the Ethics Committee 
of Kerman University of Medical Sciences (#K/91/05). 
All subjects gave informed consent before participating 
in the study.
Results
A total of 128 T2DM patients and 132 healthy adults 
were included in the study. The mean age of the subjects 
was 47.96 years (range: 20–83 years old). Mean s-IgA 
levels in the diabetic and control groups were 45.40 ± 
6.87 mg/dL and 41.17 ± 7.66 mg/dL, respectively; this 
difference between the two groups was not significant 
(P >0.050). There was no significant difference in 
s-IgA levels between genders or with age. However, 
there was a significant increase in s-IgA levels among 
patients with uncontrolled T2DM compared to those 
with controlled disease (P <0.050). Both the DMFT 
and PDI indices showed significant increases among 
the diabetic patients in comparison with the control 
group (P <0.050). Between the two groups, s-IgA levels 
were significantly higher among subjects with a higher 
PDI index. Correlations between s-IgA levels and 
other variables are shown in Table 1. 
Table 2 shows the distribution of various oral and 
dental manifestations among the two groups. s-IgA 
levels were significantly higher in subjects with oral 
candidiasis in both the diabetic and control groups. 
Tongue blade signs were positive for two subjects 
in the control group and 38 patients in the diabetic 
group. s-IgA levels were significantly higher for diabetic 
patients with xerostomia in comparison to the control 
subjects (P = 0.050). Diabetic patients also suffered 
from denture stomatitis more frequently than control 
subjects with significantly higher s-IgA levels (P ≤0.050). 
Discussion
As patients with systemic diseases such as DM 
become better educated regarding self-management 
Table 1: Correlation between salivary secretory 
immunoglobulin A concentrations and other variables 
among control and diabetic subjects in Kerman, Iran 
(N = 260)





































s-IgA = salivary secretory immunoglobulin A; HbA1C = glycated 
haemoglobin; FBS = fasting blood sugar; DMFT = decayed, missing or 
filled teeth; PDI = periodontal index. *Highly statistically significant at 
P <0.001. †Statistically significant at P <0.050.
Table 2: Comparison between salivary secretory immunoglobulin 
A levels and oral and dental manifestations among control and 
diabetic subjects in Kerman, Iran (N = 260)
Oral/dental 
manifestation













79.5 ± 16.5 0.010* 67.5 ± 10.6 0.006*
Erythematous 
candidiasis
- - 74.0 ± 16.8 0.160




- - 35.7 ± 15.9 0.810
Denture 
stomatitis
64.1 ± 22.9 0.280 71.4 ± 14.7 0.002
Angular 
cheilitis
95.0 ± 25.0 0.010* 89.2 ± 27.9 0.110
Lichenoid 
reactions
34.6 ± 6.6 0.880 126.5 ± 76.5 0.460
Frequent 
abscesses
- - 35.0 ± 6.5 0.650
Xerostomia 35.0 ± 15.0 0.890 51.8 ± 7.5 0.050*
IgA = immunoglobulin A; SE = standard error. *Statistically significant at P ≤0.05.
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and beneficial lifestyle choices, they are increasingly 
seeking to address their oral health issues.13 While 
various research has focused on diabetic subjects, few 
studies have evaluated salivary immunoglobulin levels 
among this patient population. Unlike other body fluids, 
saliva is easily accessible and there is therefore no need 
for aggressive sampling techniques in order to make a 
diagnosis or determine the prognosis of a disease. As 
such, many researchers prefer to use saliva instead of 
blood for sampling purposes.14,15 Saliva is a complex 
biological fluid and conditions which affect saliva 
production—such as xerostomia and saliva excretion 
dysfunction—decrease its buffering and cleansing 
capacity. In addition, neuropathic disturbances in 
diabetic patients can influence the development of 
dental caries and periodontal diseases.16
Within the oral cavity, s-IgA can act as the first 
line of defence against pathogens that affect mucous 
membranes by preventing the aggregation and 
adhesion of bacteria to the mucosa and neutralising 
enzymes, toxins and viruses.10 The concentrations of 
various salivary elements, such as s-IgA, have been 
investigated in a number of systemic diseases as well 
as many oral conditions, including periodontitis, 
xerostomia, lichen planus and smoking-induced oral 
diseases.14,17–21 Immune suppression or disturbances 
have been observed in diabetic patients;2 it is possible 
that T2DM affects the secretion of IgA in the saliva 
and, consequently, the defence reaction of the mucosa.
In the present study, s-IgA levels in diabetic 
patients were not significantly higher in comparison 
with non-diabetic individuals. This result is similar 
to those seen in previous studies.5–7,9,22 In contrast, 
Mohiti-Ardekani et al. demonstrated that s-IgA levels 
in diabetic patients were higher than in non-diabetics.1 
Other studies have also found higher s-IgA levels in 
diabetic patients.1,22 Discrepancies between these 
results could be attributed to differences in study 
designs and sampling and measuring techniques (e.g. 
the use of stimulated versus unstimulated saliva or 
immunoturbidimetric versus immunonephelometric 
methods).5 s-IgA levels were considerably higher 
in patients with uncontrolled T2DM in the current 
study. Harrison et al. and Malicka et al. found similarly 
high s-IgA levels in patients with poorly controlled 
diabetes.10,24
In the current research, there was a significant 
positive relationship between s-IgA and PDI and 
DMFT indices in both groups, suggesting that the 
innate immune system tries to synthesise high levels 
of IgA to reduce periodontal tissue infections.10 In 
addition, Kakoei et al. also noted a positive association 
between high salivary glucose levels and DMFT and 
PDI indices in diabetic patients.25 This is compatible 
with other findings showing that s-IgA levels 
were significantly higher in diabetic patients with 
periodontitis.10,18,26 Using the gingival and modified 
sulcus bleeding indices, Malicka et al. reported that the 
periodontal status of diabetic patients was significantly 
worse than that of healthy subjects.12 Ranadheer et 
al. showed that s-IgA levels were significantly higher 
among individuals with more than three DMFT.15 
In studies by Bakianian Vaziri et al. and Lopez et al., 
diabetic patients had significantly increased numbers 
of DMFT in comparison with healthy subjects.5,27 
In the current study, the prevalence of oral 
candidiasis was significantly higher in the subjects 
with higher s-IgA levels in both groups; this is 
consistent with the results observed by Jaganathan 
et al.28 However, no significant relationship between 
s-IgA and oral lichen planus was found. This correlates 
with previous research by Divya et al., who did not 
report any significant association between s-IgA 
levels and pre-cancerous lesions like lichen planus.20 
In contrast, Ghalayani et al. found higher s-IgA levels 
in patients with oral lichen planus in comparison with 
normal individuals.21 In the present study, a significant 
increase in s-IgA levels was found in diabetic patients 
with denture stomatitis. A study by Papova et al. also 
showed that s-IgA levels in patients with denture 
stomatitis were significantly higher in comparison 
to a control group.29 The results of the current study 
differed from those observed in a study by Wilson et 
al., who found that that s-IgA levels were significantly 
lower in denture wearers with denture stomatitis in 
comparison to healthy subjects.30 
Changes in the function and components of saliva 
as a result of different conditions among diabetic 
patients (e.g. dental caries, periodontitis, burning 
mouth and sensory problems) are not yet fully 
understood. Previous investigations have shown the 
efficacy of the buffering capacity and cleansing effect 
of saliva in negating some of these changes.16 However, 
the differences in s-IgA levels in different studies 
could be attributed to different sampling techniques 
or detection methods. One of the limitations of the 
current study was an inability to assess oral hygiene 
among the subjects. Further investigations are 
recommended to detect salivary immunoglobulins 
among diabetic patients in order to determine a 
precise and more reliable technique to predict and 
manage oral manifestations of the disease.
Conclusion
The s-IgA levels of the diabetic patients were not 
significantly higher than those of the control group 
among the studied population. In both groups, subjects 
with a higher number of DMFT, greater PDI scores 
and oral candidiasis were found to have significantly 
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higher s-IgA levels. Among diabetic patients, 
significantly higher s-IgA levels were concomitant 
with xerostomia and denture stomatitis. Furthermore, 
s-IgA levels were found to be significantly elevated 
in patients with uncontrolled T2DM compared to 
those with controlled T2DM. Further research is 
needed to investigate s-IgA concentrations among 
diabetic patients in order to aid in the prediction and 
management of oral manifestations.
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